A QS21+ CpG-Adjuvanted Rabies Virus G Subunit Vaccine Elicits Superior Humoral and Moderate Cellular Immunity.

ABSTRACT:

Background

Rabies remains a fatal zoonotic disease caused by rabies virus (RABV), posing substantial global health challenges. Current vaccine production faces challenges in manufacturing efficiency and cost-effectiveness. The RABV glycoprotein (RABV-G) serves as the key antigen for eliciting protective immunity.

Methods

We developed a novel QS21+CpG-adjuvanted RABV-G subunit vaccine and systematically compared its performance against three control formulations: mRNA vaccine composed of H270P-targeted mutation packaged in lipid nanoparticles (LNP), named LNP-mRNA-G-H270P, commercial inactivated vaccine, and alum-adjuvanted RABV-G subunit vaccine.

Results

The result show that the G+QS21+CpG subunit vaccine elicited superior humoral immunity, as evidenced by significant

SUBMITTER: Cao H 

PROVIDER: S-EPMC12390428 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature